- Home
- OTLK vs CTSO Comparison
OTLK vs CTSO Comparison
Compare OTLK & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- CTSO
- Stock Information
- Founded
- OTLK 2010
- CTSO 1997
- Country
- OTLK United States
- CTSO United States
- Employees
- OTLK N/A
- CTSO N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- CTSO Medical/Dental Instruments
- Sector
- OTLK Health Care
- CTSO Health Care
- Exchange
- OTLK Nasdaq
- CTSO Nasdaq
- Market Cap
- OTLK 42.8M
- CTSO 45.3M
- IPO Year
- OTLK 2016
- CTSO N/A
- Fundamental
- Price
- OTLK $1.69
- CTSO $0.78
- Analyst Decision
- OTLK Buy
- CTSO Buy
- Analyst Count
- OTLK 5
- CTSO 2
- Target Price
- OTLK $5.25
- CTSO $5.38
- AVG Volume (30 Days)
- OTLK 4.5M
- CTSO 133.1K
- Earning Date
- OTLK 12-26-2025
- CTSO 11-13-2025
- Dividend Yield
- OTLK N/A
- CTSO N/A
- EPS Growth
- OTLK N/A
- CTSO N/A
- EPS
- OTLK N/A
- CTSO N/A
- Revenue
- OTLK $1,505,322.00
- CTSO $36,979,520.00
- Revenue This Year
- OTLK N/A
- CTSO $11.93
- Revenue Next Year
- OTLK $342.80
- CTSO $21.22
- P/E Ratio
- OTLK N/A
- CTSO N/A
- Revenue Growth
- OTLK N/A
- CTSO 23.89
- 52 Week Low
- OTLK $0.79
- CTSO $0.60
- 52 Week High
- OTLK $5.18
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- OTLK 59.10
- CTSO 59.39
- Support Level
- OTLK $1.76
- CTSO $0.60
- Resistance Level
- OTLK $2.02
- CTSO $0.85
- Average True Range (ATR)
- OTLK 0.20
- CTSO 0.07
- MACD
- OTLK 0.04
- CTSO 0.02
- Stochastic Oscillator
- OTLK 59.38
- CTSO 92.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.